Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Harnessing Patients' Own Natural Killer Cells to Fight Ovarian Cancer

EF 2016-17

Résumé
Ovarian cancer is the most deadly gynecological cancer: over half of women diagnosed will not survive 5 years. As such, there is a critical need for effective treatments. Harnessing the body's natural immune defenses against cancer is emerging as a promising treatment modality. Natural Killer (NK) cells are immune cells with the capacity to kill cancer cells without harming healthy cells. NK cell therapy has proven effective against leukemia whereby NK cells are extracted from blood, clonally expanded, and injected into a patient. The current project will explore the use of NK cells as a novel therapy for ovarian cancer. Despite their therapeutic potential, NK cells have had limited success against solid tumours, such as ovarian cancer, due to the hostile environment surrounding tumours which inhibits NK cell function. Thus, understanding how the tumour environment alters NK cells is paramount to developing strategies to overcome this inhibition and expand NK cell therapeutic ability to solid tumours. Using a model of primary human ovarian cancer in mice established by our laboratory, this project will work to uncover the changes in NK cells that inhibit their function after exposure to the ovarian cancer environment. As well, we will explore a strategy to enhance NK cell function against ovarian cancer using an activation method that has proven effective against leukemia. Overall, this project will provide an improved understanding of NK cell inhibition by the ovarian cancer environment and identify strategies to harness the therapeutic potential of NK cells against ovarian and other cancers. This project will lay the groundwork for an effective NK cell therapy against ovarian cancer and address the pressing need to improve survival rates.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
367292
Name
Poznanski Sophie M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Harnessing Patients' Own Natural Killer Cells to Fight Ovarian Cancer
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Therapy; Immunology; Immunotherapy; Nk Cells; Ovarian Cancer; Tumour Microenvironment
Abstract
Ovarian cancer is the most deadly gynecological cancer: over half of women diagnosed will not survive 5 years. As such, there is a critical need for effective treatments. Harnessing the body's natural immune defenses against cancer is emerging as a promising treatment modality. Natural Killer (NK) cells are immune cells with the capacity to kill cancer cells without harming healthy cells. NK cell therapy has proven effective against leukemia whereby NK cells are extracted from blood, clonally expanded, and injected into a patient. The current project will explore the use of NK cells as a novel therapy for ovarian cancer. Despite their therapeutic potential, NK cells have had limited success against solid tumours, such as ovarian cancer, due to the hostile environment surrounding tumours which inhibits NK cell function. Thus, understanding how the tumour environment alters NK cells is paramount to developing strategies to overcome this inhibition and expand NK cell therapeutic ability to solid tumours. Using a model of primary human ovarian cancer in mice established by our laboratory, this project will work to uncover the changes in NK cells that inhibit their function after exposure to the ovarian cancer environment. As well, we will explore a strategy to enhance NK cell function against ovarian cancer using an activation method that has proven effective against leukemia. Overall, this project will provide an improved understanding of NK cell inhibition by the ovarian cancer environment and identify strategies to harness the therapeutic potential of NK cells against ovarian and other cancers. This project will lay the groundwork for an effective NK cell therapy against ovarian cancer and address the pressing need to improve survival rates.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Poznanski, Sophie M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~